- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-2–based therapies in cancer
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 14, Issue 670, Pages -
Publisher
American Association for the Advancement of Science (AAAS)
Online
2022-11-10
DOI
10.1126/scitranslmed.abo5409
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate
- (2022) Rosemina Merchant et al. Journal for ImmunoTherapy of Cancer
- Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression
- (2022) Christopher J. Nirschl et al. Cancer Immunology Research
- Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
- (2022) Ulka N. Vaishampayan et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.
- (2022) James Robert Vasselli et al. JOURNAL OF CLINICAL ONCOLOGY
- TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
- (2022) David B Rosen et al. Journal for ImmunoTherapy of Cancer
- PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
- (2022) Laura Codarri Deak et al. NATURE
- Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.
- (2021) Jennifer O'Neil et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.
- (2021) Antoine Italiano et al. JOURNAL OF CLINICAL ONCOLOGY
- An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
- (2021) Jerod L. Ptacin et al. Nature Communications
- CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
- (2020) Steven N Quayle et al. CLINICAL CANCER RESEARCH
- ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
- (2020) Jared E Lopes et al. Journal for ImmunoTherapy of Cancer
- Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
- (2020) Miro E. Raeber et al. Science Translational Medicine
- An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
- (2020) Dilara Sahin et al. Nature Communications
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
- (2019) Benjamin Weide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The role of cytokines in T-cell memory in health and disease
- (2018) Miro E. Raeber et al. IMMUNOLOGICAL REVIEWS
- Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years’ Experience
- (2017) Richard Bright et al. JOURNAL OF IMMUNOTHERAPY
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
- (2015) Suman Mitra et al. IMMUNITY
- The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer
- (2015) Chiara Catania et al. Cell Adhesion & Migration
- A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
- (2012) Silke Gillessen et al. EUROPEAN JOURNAL OF CANCER
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies
- (2011) M. N. Fishman et al. CLINICAL CANCER RESEARCH
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now